Egypt s Minister of Health and Population Khaled Abdel-Ghaffar during the signing of four cooperation agreements with international pharmaceutical companies on Thursday, on the sidelines of PHDC 2023
These agreements were signed on the sidelines of the Global Congress on Population, Health, and Development (PHDC 2023).
The PHDC is taking place in Egypt for the first time in the New Administrative Capital from 5-8 September and aims to highlight the interrelation between population, health, and sustainable development.
According to a health ministry statement, the first agreement was signed with Bayer Limited Egypt, a subsidiary of the German company Bayer AG.
This agreement aims to establish two excellence centres equipped with state-of-the-art devices to train doctors in the latest family planning methods.
Additionally, the agreement includes the provision of intrauterine devices (IUDs) to support the health ministry's family planning sector.
The second agreement was signed with the French company Sanofi to support national efforts combating genetic and rare diseases. Sanofi will aid in developing a comprehensive training program for medical teams working in genetic disease diagnosis and treatment centres, as well as neonatal intensive care units nationwide.
The third agreement, signed with AstraZeneca Egypt, will launch a campaign for the early diagnosis of lung diseases, especially tumours, and enhance medical services to patients suffering from these problems.
The agreement contributes towards a presidential initiative for early detection and treatment of cancerous tumours, specifically lung cancer.
The fourth cooperation agreement with Merck Limited Egypt supports the same presidential initiative focusing on the detection of colorectal cancer.
The agreement intends to facilitate the organization of scientific training programs for medical professionals in various specialities participating in the presidential initiative, as well as genetic testing for colorectal and rectal cancer patients.
Short link: